Pharmaceuticals

A novel transdermal curcumin gel shows significant pain reduction in a clinical trial, offering a potential non-oral alternative for millions with knee pain.

With a key data readout looming for its chronic cough drug, Nocion adds a renowned dealmaker to its board, fueling speculation of a potential acquisition.

With a unique drug that preserves muscle while shedding fat, a newly fortified biotech is set to challenge the titans of the weight-loss market.

A new investigation shows drug companies make $31 in profit for every $1 paid in penalties, suggesting fines are just a cost of doing business.

As regulators demand PBM reform, Liviniti marks 15 years and 1 million members served with its pioneering transparent, pass-through pricing model.

Veteran biotech CEO Paul Sekhri joins investor Petrichor, signaling a strategic shift where hands-on leadership is now paramount in life sciences investing.

Biotech veteran Dr. Vince O'Neill joins Mosaic Therapeutics to spearhead its synergistic precision oncology pipeline, aiming to transform cancer treatment.

Parnell’s nixiFLOR, the first generic of Resflor Gold®, offers a cost-effective new weapon for ranchers battling Bovine Respiratory Disease.

As China surpasses the US in key research metrics, a new English platform aims to bridge the information gap for global scientists and innovators.

A stark new benchmark study reveals poor survival in late-stage GvHD, just as MaaT Pharma’s microbiome therapy shows dramatically better outcomes.

The biopharma firm touts transformative drug data ahead, but with cash for only month-to-month operations, its future hangs by a precarious thread.

The American Skin Association launches SKINsight, a podcast series uniting top doctors and patients to demystify skin disease for millions of listeners.

Facing a severe cash crunch and delisting threats, the biotech firm is halting development and seeking buyers for its innovative cancer drug pipeline.

OBIO awards $100K to a cancer therapy startup and launches a new training program, directly addressing the systemic funding barriers for women in life sciences.

ValGenesis and Validator K.K. join forces to bring advanced digital validation to Japan, tackling labor shortages and accelerating Pharma 4.0 goals.

Michael Farah's move to Orchard Investment Partners signals a major play in the booming continuation vehicle space, leveraging deep healthcare expertise.

A novel drug aims to break down resistance in hard-to-treat lung and bile duct cancers, with key data set for a major oncology conference.

As its novel oral antiviral for the 'winter vomiting bug' enters a pivotal human study, Cocrystal Pharma balances hope with financial prudence.

A key U.S. patent extends protection for a promising CRPS-1 drug, paving the way for a potential first-in-class treatment for the debilitating condition.

Longhorn Diagnostics unveils LHNVD-501, a novel antibody targeting a universal bacterial component, offering a new front against AMR and chronic inflammation.